HHS Part B Plan Gets Pharma's Attention, But Savings Target May Be Too High
Executive Summary
Regeneron analysis of policy's potential impact on Eylea signals that MA plans will face overwhelming challenge to achieve 20% savings in Part B.
You may also be interested in...
Attralus Raises $116m To Advance Amyloidosis-Clearing Pipeline
The company intends to use the series B cash to bring the first of its pan-amyloid removal (PAR) therapies into the clinic, while also advancing a diagnostic tool for systemic amyloidosis.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.
An Artificial Intelligence Milestone For US FDA
A project to validate a depression severity measurement tool that employs artificial intelligence for use in drug trials is moving forward at FDA. The milestone is a sign of things to come – and of the incremental process for AI adoption by the regulator.